Abby Hardy, Author at BioTuesdays

Developments

vTv Therapeutics’ Phase 2 diabetes trial meets primary objective

vTv Therapeutics’ (NASDAQ:VTVT) Phase 2 trial of TTP399 in Type 1 diabetes (T1D) patients met its primary objective by demonstrating statistically significant improvements in HbA1c compared to placebo. The company...

February 10, 2020

Developments

Catalyst Biosciences reports positive Phase 2b data from hemophilia trial

Catalyst Biosciences (NASDAQ:CBIO) reported positive results from its Phase 2b trial of DalcA, a subcutaneously administered Factor IX (FIX) therapy for the treatment of hemophilia B. The study was designed to evaluate...

February 7, 2020

Developments

Soricimed reports first cohort completion in Phase 1b trial of SOR-C13

Closely-held Soricimed Biopharma reported that the MD Anderson Cancer Center completed the first cohort in its investigator-initiated trial of Soricimed’s SOR-C13. The trial, launched in September 2019, is building on...

February 7, 2020

Developments

Hepion elucidates CRV431’s mechanism of action in NASH

Hepion Pharmaceuticals (NASDAQ:HEPA) released a video illustrating CRV431’s mechanism of action in non-alcoholic steatohepatitis (NASH). CRV431 inhibits multiple forms of cyclophilins to impact multiple stages of NASH...

February 4, 2020

Executive Moves

Verona Pharma announces senior management changes

Verona Pharma (NASDAQ:VRNA) has appointed David Zaccardelli as president, CEO, and director; and Mark Hahn as CFO. Mr. Zaccardelli will replace current CEO, Jan-Anders Karlsson, who is retiring. Mr. Zaccardelli...

February 3, 2020

Developments

Anavex gets fast track designation for Rett Syndrome drug candidate

The FDA granted fast track designation to Anavex Life Sciences’ (NASDAQ:AVXL) ANAVEX2-73 for the treatment of Rett syndrome. Rett syndrome is a genetic neurodevelopmental disorder characterized by severe physical and...

February 3, 2020

Developments

Aprea Therapeutics gets breakthrough therapy designation for myelodysplastic syndrome treatment

Aprea Therapeutics (NASDAQ:APRE) received FDA breakthrough designation for APR-246, in combination with azacytidine, for the treatment of myelodysplastic syndromes (MDS) with a susceptible tumor suppressor protein p53...

January 30, 2020

Developments

Pulmatrix gets fast track designation for Pulmazole

Pulmatrix (NASDAQ:PULM) received FDA fast track designation for Pulmazole, an inhaled itraconazole antifungal for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma. The safety...

January 30, 2020

Developments

FDA clears VistaGen’s IND for Phase 2 levodopa-induced dyskinesia study

The FDA cleared VistaGen Therapeutics’ (NASDAQ:VTGN) IND for AV-101 for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease, enabling the company to proceed with Phase 2...

January 30, 2020

Developments

Hepion reports positive results of CRV431 in expanded human liver study

Hepion Pharmaceuticals (NASDAQ:HEPA) reported that its non-alcoholic steatohepatitis (NASH) candidate, CRV431, demonstrated superior antifibrotic efficacy in an expanded human liver study. The study design and its...

January 28, 2020

Author - Abby Hardy

vTv Therapeutics’ Phase 2 diabetes trial meets primary objective

Catalyst Biosciences reports positive Phase 2b data from hemophilia trial

Soricimed reports first cohort completion in Phase 1b trial of SOR-C13

Hepion elucidates CRV431’s mechanism of action in NASH

Verona Pharma announces senior management changes

Anavex gets fast track designation for Rett Syndrome drug candidate

Aprea Therapeutics gets breakthrough therapy designation for myelodysplastic syndrome treatment

Pulmatrix gets fast track designation for Pulmazole

FDA clears VistaGen’s IND for Phase 2 levodopa-induced dyskinesia study

Hepion reports positive results of CRV431 in expanded human liver study

Subscribe